Juluca

Dolutegravir sodium and rilpivirine hydrochloride, the active ingredient in Juluca, is a antiretroviral (integrase strand transfer inhibitor + non‑nucleoside reverse transcriptase inhibitor) presented as a 50 mg dolutegravir sodium / 25 mg rilpivirine hydrochloride film‑coated tablet for oral use. It treats HIV‑1 infection in treatment‑experienced adults with no prior resistance to integrase inhibitors or NNRTIs.

GNH USA supplies Juluca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juluca is indicated for HIV‑1 infection, acting on viral replication through integrase inhibition and reverse‑transcriptase inhibition.

HIV‑1 treatment‑experienced adult infection: used as a complete regimen for adults who have previously received antiretroviral therapy and have no documented resistance to integrase inhibitors or NNRTIs. Maintenance therapy for HIV‑1 infection: provides ongoing viral suppression as a once‑daily oral regimen. Switch therapy for virologically suppressed patients: enables transition from multi‑tablet regimens to a single‑tablet regimen while maintaining efficacy.

Adverse reactions reported with Juluca vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient headache. - Diarrhea: loose stools. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: rash, fever, eosinophilia, or anaphylaxis. - Elevated liver enzymes: potential hepatotoxicity requiring monitoring.

Before initiating Juluca, several clinical considerations should be evaluated.

Assess resistance profile: confirm no prior resistance to integrase inhibitors or NNRTIs. Monitor hepatic function: check liver enzymes periodically during therapy. Evaluate renal function: consider dose adjustment in patients with severe renal impairment. Review concomitant medications: identify potential drug‑drug interactions that may affect efficacy or safety. Pregnancy and breastfeeding: use only if the expected benefit justifies the potential risk, as data are limited. Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Juluca may interact with other medicines; interactions are classified by their clinical significance.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that markedly reduces dolutegravir and rilpivirine concentrations. - Antacids containing polyvalent cations (e.g., aluminum, magnesium): decrease rilpivirine absorption when taken concurrently. - St. John’s wort: potent CYP3A4 inducer that lowers rilpivirine levels.

Moderate Interactions (Monitor Closely): - Hepatitis C protease inhibitors (e.g., boceprevir): may increase dolutegravir exposure. - Metformin: dolutegravir can increase plasma metformin concentrations, requiring monitoring. - Oral contraceptives: rilpivirine may reduce contraceptive efficacy; advise additional non‑hormonal methods.